XELODA (Capecitabine) 500mg

XELODA (capecitabine)is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:

• Adjuvant Colon Cancer

– Patients with Dukes’ C colon cancer

• Metastatic Colorectal Cancer

– First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred

• Metastatic Breast Cancer

–  In combination with docetaxel after failure of prior anthracycline- containing therapy

–  As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen

ADVERSE REACTIONS

Most common adverse reactions (≥30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. Other adverse reactions, including serious adverse reactions, have been reported.